Metformin combined with p38 MAPK inhibitor improves cisplatin sensitivity in cisplatin-resistant ovarian cancer

The aim of the present study was to determine the effects of metformin, combined with a p38 mitogen-activated protein kinase (MAPK) inhibitor, on the sensitivity of cisplatin-resistant ovarian cancer to cisplatin. The expression and distribution of phosphorylated p38 MAPK (P-p38 MAPK) was confirmed...

Descripción completa

Detalles Bibliográficos
Autores principales: XIE, YA, PENG, ZHENG, SHI, MINGXING, JI, MEI, GUO, HONGJUN, SHI, HUIRONG
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2014
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4214348/
https://www.ncbi.nlm.nih.gov/pubmed/25118792
http://dx.doi.org/10.3892/mmr.2014.2490

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4214348/
https://www.ncbi.nlm.nih.gov/pubmed/25118792
http://dx.doi.org/10.3892/mmr.2014.2490

Ejemplares similares